ISOPP 2023 One Day Masterclasses

Sunday, March 5, 2023, Seville, Spain

Barcelo Sevilla Renacimiento, Seville, Spain

A Masterclass is a practical workshop, specific to the needs of oncology pharmacy practitioners which is facilitated by ISOPP leaders and oncology pharmacy experts.

These two half day masterclasses are available to ISOPP and GEDEFO members. In addition, the Biosimilars Workshop is also open to OPAB Program registrants who have completed the program.  If you are not an ISOPP member in 2023 and would like to register for a Masterclass, please join ISOPP and pay your member fees prior to registering. 2023 ISOPP membership renewal/application opens in December 2022.  Alternatively, join GEDEFO.

In addition to hands on learning, participants have access to presentation materials post event. 

“Most impressive because I had a chance to learn from pharmacists from different countries”.  (2019 London Masterclass Participant)


Immunotherapy Masterclass

It is recognized that there is an essential role for the oncology pharmacist in improving patient outcomes for patients receiving immunotherapy with immune checkpoint inhibitors and CAR T-cell therapy, as is outlined in the ISOPP Position Statement on The Role of Oncology Pharmacy Practitioners in Immunotherapy Treatment with Immune Checkpoint Inhibitors for Malignant Conditions (JOPP Apr 5, 2022).  This 4.5 hour program will support oncology pharmacists in developing a clinical understanding of immunotherapy and the essential role that pharmacists play at the forefront of therapy management.

  • Review and discuss key immunotherapy concepts and the mechanism of action of immune checkpoint inhibitors and CAR T-cell therapy.
  • Describe the fundamentals of care with immune checkpoint inhibitors including dosing, adverse effects and management of patients on treatment.
  • Describe the fundamentals of care with CAR T-cell therapy including pharmacokinetics, adverse effects and management of patients on treatment.
  • Using case studies, discuss the management of patient on immune checkpoint inhibitors and CAR T-cell therapy

Program - 8:00 - 12:15

8:00 - 8:05 Welcome and Introductions – Lynne Nakashima

8:05 - 8:30 Basic Cancer Immunotherapy Concepts – Lynne Nakashima

8:30 - 9:15 Fundamentals of Care with Immune Checkpoint Inhibitors – Alexandre Chan

9:15 - 10:00 Fundamentals of Care with CAR T-cell therapy – Alison Palumbo

10:00 - 10:20 Break (20 mins)

10:20 - 11:50 Case Studies – Alex Chan and Alison Palumbo

11:50 - 12:05 ISOPP Position Statement and Closing Remarks – Lynne Nakashima

  • Alexandre Chan, Founding Chair and Professor of Clinical Pharmacy, Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, USA
  • Lynne Nakashima, Senior Director, Provincial Pharmacy, BC Cancer, Vancouver, BC, Canada
  • Alison Palumbo, Clinical Oncology Pharmacist, Oregon Health & Science University, Portland, Oregon, USA
  • Lynne Nakashima, Senior Director, Provincial Pharmacy, BC Cancer, Vancouver, BC, Canada
Presenter Biographies

Alex Chan is a Professor and Chair of the Department of Clinical Pharmacy Practice at University of California, Irvine, United States. He is an Oncology Pharmacist at the Chao Family Comprehensive Cancer Center, providing supportive care to patients undergoing chemotherapy and immunotherapy. He is also appointed as a Visiting Professor at the National Cancer Center Singapore. A board-certified specialist in Pharmacotherapy and Oncology Pharmacy, Alex has published over 240 full-length peer-reviewed manuscripts in a wide array of cancer supportive care and survivorship topics. Alex is an elected Fellow of the American College of Clinical Pharmacy and the International Society of Oncology Pharmacy Practitioners (ISOPP). He is a Past-President of ISOPP as well as a Board Member for MASCC. He is also an incoming Specialty Council member for the Board of Pharmacy Specialties (BPS) Oncology Pharmacy Specialty Council.


Dr. Lynne Nakashima received her BSc(Pharm) from the University of British Columbia, Canada and her PharmD from the University of North Carolina at Chapel Hill, USA.  She is currently the Senior Director, Provincial Pharmacy at BC Cancer where she is responsible for pharmacy professional practice, the cancer drug formulary and coordinates a team of advanced practice pharmacists and pharmacy technicians.  Lynne has been a member of ISOPP since its beginnings and is currently the Chair of the Immunotherapy Task Force, a member of the Engagement and Communications Committee and a member of the JOPP Editorial Board.  In her spare time, she enjoys golfing, reading and collecting sheep.



Alison Palumbo is a Clinical Oncology Pharmacist at Oregon Health and Science University (OHSU) in Portland, Oregon, USA.  She completed her Doctor of Pharmacy and Master in Public Health degrees at the University of Kentucky.  She completed her PGY1 Pharmacy Practice Residency at the University of Michigan Medicine and PGY2 Oncology Pharmacy Residency at the University of Washington Medicine.  She has been practicing at OHSU for 8 years and her special interests include breast cancer, supportive care and global health.  She is also the founder and president of the nonprofit organization, Banyan Tree Clinics.  In her free time, she also enjoys traveling, hanging out with her dog, Ghost, and Crossfit.






Biosimilars and Implementation Masterclass

This 4.5 hour workshop will explore logistic considerations, strategies and resources to integrate biosimilars into clinical practice. 

  • Discuss logistic considerations that are important in the incorporation of biosimilars into clinical practice
  • Demonstrate the ability to provide education on biosimilar use to both patients and healthcare professionals (best practices) 
  • Identify strategies and resources that can facilitate the process of implementing biosimilars in clinical practice
Program - 13:15 - 17:30

13:15 - 14:45 Test your knowledge quiz, Biosimilar implementation in practice (Presentation), Quiz answers

14:45 - 15:00 Group exercise

15:00 - 15:30 Break (30 mins)

15:30 - 16:00 Feedback from groups

16:00 - 17:00 Implementation case studies (presentation)

17:00 - 17:30 Final questions and close

  • Emma Foreman, Consultant Pharmacist, The Royal Marsden NHS Foundation Trust, UK
  • Joseph Bubalo, Oncology Clinical Specialist, OHSU Hospital and Clinics, USA

Presenter Biographies

Joseph Bubalo, Pharm.D. BCPS, BCOP, is an oncology pharmacotherapy specialist with Oregon Health & Science University (OHSU) in Portland, Oregon and an Assistant Professor of Medicine with the Division of Hematology and Medical Oncology.  He has been active in the clinical care of oncology and stem cell transplant and cellular therapy patients for over 25 years and has received research grants investigating ways to improve multiple areas of supportive care in these patients.  He continues to look for ways to decrease the symptoms associated with antineoplastic and associated therapies.  Joe is an ISOPP member and has participated in the organization in multiple roles over the years, recently coauthoring ISOPP’s Biosimilar position statement.


Emma Foreman is a Consultant Pharmacist with Royal Marsden NHS Foundation Trust, London, UK. Emma has been a hospital pharmacist for over 20 years, working in a variety of different hospitals from small district generals to large teaching hospitals – including a tiny mission hospital in Ghana! She specialised in oncology in 2001 taking on both technical and clinical roles, qualifying as an independent prescriber in 2010 and completing an MSc in clinical oncology at Birmingham University in 2011.  
Emma is currently a Consultant Pharmacist at the UK’s largest cancer centre, The Royal Marsden, where she works with a multidisciplinary team to innovate and implement chemotherapy service improvements as well as working with the pharmacy team to develop and promote the role of pharmacists as advanced practitioners.  She is currently Vice-chair of the British Oncology Pharmacy Association (BOPA) and Chair of the International Society for Oncology Pharmacy Practice (ISOPP) Biosimilars Taskforce.